Global Diabetic Neuropathy Drugs Market 2021-2025

Global Diabetic Neuropathy Drugs Market 2021-2025

Technavio has been monitoring the diabetic neuropathy drugs market and it is poised to grow by $ 2.37 bn during 2021-2025, progressing at a CAGR of 12.20% during the forecast period. Our report on the diabetic neuropathy drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of diabetic neuropathy and new drug approvals and strong drug pipeline. In addition, the increasing prevalence of diabetic neuropathy is anticipated to boost the growth of the market as well.

The diabetic neuropathy drugs market analysis includes the product segment and geographic landscape.

Technavio's diabetic neuropathy drugs market is segmented as below:

By Product

• Calcium channel alpha-2-delta ligand
• SNRIs and TCAs
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• ROW

This study identifies the rising awareness about diabetic neuropathyas one of the prime reasons driving the diabetic neuropathy drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on diabetic neuropathy drugs market covers the following areas:

• Diabetic neuropathy drugs market sizing
• Diabetic neuropathy drugs market forecast
• Diabetic neuropathy drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading diabetic neuropathy drugs market vendors that include Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Grunenthal GmbH, Johnson and Johnson Inc., NeuroBo Pharmaceuticals Inc., Novartis AG, and Pfizer Inc. Also, the diabetic neuropathy drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Companies Mentioned

Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Grunenthal GmbH, Johnson and Johnson Inc., NeuroBo Pharmaceuticals Inc., Novartis AG, Pfizer Inc.